Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Total Liabilities: 2022-2024

Historic Total Liabilities for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $107.1 million.

  • NewAmsterdam Pharma Co N.V's Total Liabilities fell 3.27% to $58.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 3.27%. This contributed to the annual value of $107.1 million for FY2024, which is 82.47% up from last year.
  • NewAmsterdam Pharma Co N.V's Total Liabilities amounted to $107.1 million in FY2024, which was up 82.47% from $58.7 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's 5-year Total Liabilities high stood at $107.1 million for FY2024, and its period low was $48.4 million during FY2022.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Total Liabilities had a median value of $58.7 million in 2023 and averaged $71.4 million.
  • Data for NewAmsterdam Pharma Co N.V's Total Liabilities shows a peak YoY surged of 82.47% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Total Liabilities stood at $48.4 million in 2022, then increased by 21.21% to $58.7 million in 2023, then soared by 82.47% to $107.1 million in 2024.